{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/A4001101","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT01275625","ctis_id":"","HasResults":"true","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Nonrandomized Trial","arm_groups":[{"arm_group_label":"Treatment","arm_group_description":"Single arm study of combivir and maraviroc for 48 weeks","arm_type":"Experimental"}],"assignment":"Single Group","brief_summary":"One hundred subjects in Russia will be treated with a combination of Combivir (zidovudine and lamivudine) and maraviroc as their first line HIV therapy. The aim is to assess the efficacy and safety of this combination in a Russian population of patients.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:51:17","criteria":"Inclusion Criteria: - Over 18 years of age. - R5 HIV infection on screening tropism test. - Viral load >1,000 copies/mL. - Never previously treated with anti-HIV medicines. Exclusion Criteria: - Previously treated with anti-HIV medicines. - Hepatitis B co-infection.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"98","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"d33906ae-6846-5422-a157-d8d98d8b55ff","internal":{"content":null,"contentDigest":"31d1e15af1ce50c68ba3ee5eccc1da13","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Over 18 years of age. - R5 HIV infection on screening tropism test. - Viral load >1,000 copies/mL. - Never previously treated with anti-HIV medicines. Exclusion Criteria: - Previously treated with anti-HIV medicines. - Hepatitis B co-infection.","interventions":[{"arm_group_label":"Treatment","intervention_description":"Combivir one tablet BD with maraviroc 300mg BD for 48 weeks","intervention_name":"HIV therapy","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":false,"keywords":["maraviroc","naive","hiv","zidovudine","lamivudine","combivir","Clade A"],"last_follow_up_date":"07/01/2013 00:00:00","links":[{"description":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001101&StudyName=Combivir%20And%20Maraviroc%20In%20Antiretroviral%20Naive%20Subjects%20In%20Russia"}],"locations":[{"City":"Saint-Petersburg","Latitude":"59.8404778","CountryDisplay":"Russia","Longitude":"30.5964013","Name":"Federal State Institution Republican clinical infectious hospital of Roszdrav","StateDisplay":null,"PostalCode":"196645","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Moscow","Latitude":"55.766642","CountryDisplay":"Russia","Longitude":"37.7393379","Name":"Federal scientific and methodological center on AIDS prophylaxis and control","StateDisplay":null,"PostalCode":"105275","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Nizhnij Novgorod","Latitude":"56.3333844","CountryDisplay":"Russia","Longitude":"44.0157962","Name":"Regional Center on AIDS and Infectious Diseases Prophylaxis and Control","StateDisplay":null,"PostalCode":"603005","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Krasnoyarsk","Latitude":"56.0109018","CountryDisplay":"Russia","Longitude":"92.8821705","Name":"Regional Center on AIDS and Infectious Diseases Prophylaxis and Control","StateDisplay":null,"PostalCode":"660049","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Volgograd","Latitude":"48.7757346","CountryDisplay":"Russia","Longitude":"44.5419165","Name":"Volgograd Regional Center on AIDS and Infectious Diseases Prophylaxis and Control","StateDisplay":null,"PostalCode":"400040","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Smolensk","Latitude":"54.8127287","CountryDisplay":"Russia","Longitude":"32.0474305","Name":"Smolensk Center on AIDS and infectious diseases prophylaxis and control","StateDisplay":null,"PostalCode":"214006","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Saint-Petersburg","Latitude":"59.9126905","CountryDisplay":"Russia","Longitude":"30.2945611","Name":"Saint-Petersburg Center on AIDS and Infectious Diseases Prophylaxis and Control","StateDisplay":null,"PostalCode":"190103","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Moscow","Latitude":"55.7868312","CountryDisplay":"Russia","Longitude":"37.6332752","Name":"Moscow regional center on AIDS and infectious diseases prophylaxis and control","StateDisplay":null,"PostalCode":"129110","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"}],"masking":"Open","maximum_age_raw":"N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"10/01/2018 22:57:09","number_of_arms":"1","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Multicenter, Open Label Study Of Maraviroc, Zidovudine And Lamivudine Twice Daily For The Treatment Of Antiretroviral Naïve HIV-Infected Patients With R5 HIV-1 In Russia","org_study_id":"A4001101","overall_contact":{"email":null,"last_name":"Pfizer CT.gov Call Center","phone":"1-800-718-1021"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"PHASE 4","primary_compl_date":"10/01/2012 00:00:00","primary_outcomes":[],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"None","lead_sponsor":"ViiV Healthcare","collaborators":["Pfizer"]},"start_date":"06/01/2011 00:00:00","study_type":"Interventional","therapeutic_area":"","citations":[],"is_section_801":true}},"pageContext":{"studyId":"A4001101"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}